Jazz’s cannabidiol therapy flunks in Japanese Phase III trial
The company’s oral solution, Epidiolex, is approved as an adjunct seizure treatment for three epileptic conditions in the US and Europe.
23 August 2024
23 August 2024
The company’s oral solution, Epidiolex, is approved as an adjunct seizure treatment for three epileptic conditions in the US and Europe.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.